Viral Infections

  • Author: Jin S. Suh, MD, FACP (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/26/16 (What's New)

Summary

  • CMV disease is best prevented by initiating and continuing ART to maintain a CD4+ cell count > 100 cells/mm3
  • Patients who have CD4+ cell counts < 100 cells/mm3 should have an annual screening by indirect ophthalmoscopy
  • Valganciclovir is the preferred treatment for maintenance therapy for CMV retinitis (Table 5) (Management Guidelines)[CDC OI]

Action required

Keywords: Cytomegalovirus (CMV), Ophthalmologic Complications

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.